Search
Novavax Shares Jump 25% Following FDA Approval of New COVID-19 Vaccine
2025-05-20 /
Read about 0 minute
Author：小编
The FDA has granted approval for Novavax's protein-based COVID-19 vaccine, Nuvaxoid, developed in partnership with Sanofi, for use in elderly individuals and those aged 12 to 64 with underlying medical conditions. As part of this collaboration, Sanofi will make milestone payments totaling $175 million and will take charge of the vaccine's commercialization efforts. This positive development has propelled Novavax's share price by a remarkable 25%. The company anticipates launching the 2025-2026 iteration of the vaccine in the upcoming fall season.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
